U.S. Markets closed
  • S&P Futures

    3,929.50
    +7.00 (+0.18%)
     
  • Dow Futures

    32,007.00
    +91.00 (+0.29%)
     
  • Nasdaq Futures

    13,320.25
    +18.25 (+0.14%)
     
  • Russell 2000 Futures

    2,297.80
    +12.70 (+0.56%)
     
  • Crude Oil

    63.42
    +0.20 (+0.32%)
     
  • Gold

    1,793.80
    -4.10 (-0.23%)
     
  • Silver

    28.08
    +0.22 (+0.78%)
     
  • EUR/USD

    1.2170
    +0.0001 (+0.0122%)
     
  • 10-Yr Bond

    1.3890
    +0.0270 (+1.98%)
     
  • Vix

    21.34
    -1.77 (-7.66%)
     
  • GBP/USD

    1.4140
    -0.0001 (-0.0071%)
     
  • USD/JPY

    105.9800
    +0.0980 (+0.0926%)
     
  • BTC-USD

    50,323.14
    +43.33 (+0.09%)
     
  • CMC Crypto 200

    1,004.34
    -10.58 (-1.04%)
     
  • FTSE 100

    6,658.97
    +33.03 (+0.50%)
     
  • Nikkei 225

    30,156.48
    +484.78 (+1.63%)
     

Portnoy Law: Lawsuit Filed On Behalf of Reata Pharmaceuticals, Inc. Investors

  • Oops!
    Something went wrong.
    Please try again later.
Portnoy Law
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Click here to join the case

LOS ANGELES, Dec. 14, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Reata Pharmaceuticals, Inc. ("Reata" or "the Company") (NASDAQ: RETA) investors that acquired securities between October 15, 2019 and August 7, 2020.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

It is alleged in the complaint that Reata made misleading and false statements to the market. Reata failed to produce MOXIe Part 2 study results from the FDA that were sufficient to support the marketing of approval for omaveloxolone for the treatment of FA without additional evidence. Based on the MOXIe Part 2 study alone, it was foreseeable that omaveloxolone would not be approved by the FDA for the treatment of FA. Reata’s public statements were false and materially misleading throughout the class period, based on these facts. Investors suffered damages when the market learned the truth about Reata.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising